Financial Review: Rapid Micro Biosystems (NASDAQ:RPID) vs. PositiveID (OTCMKTS:PSID)

Rapid Micro Biosystems (NASDAQ:RPID) and PositiveID (OTCMKTS:PSID) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Insider and Institutional Ownership

52.6% of Rapid Micro Biosystems shares are owned by institutional investors. 30.4% of Rapid Micro Biosystems shares are owned by company insiders. Comparatively, 48.4% of PositiveID shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Rapid Micro Biosystems and PositiveID”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapid Micro Biosystems	$28.05 million	3.70	-$52.47 million	($1.08)	-2.22
PositiveID	N/A	N/A	N/A	N/A	N/A

PositiveID has lower revenue, but higher earnings than Rapid Micro Biosystems.

Profitability

This table compares Rapid Micro Biosystems and PositiveID’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapid Micro Biosystems	-184.93%	-48.05%	-39.18%
PositiveID	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and price targets for Rapid Micro Biosystems and PositiveID, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapid Micro Biosystems	0	0	0	1	4.00
PositiveID	0	0	0	0	0.00

Rapid Micro Biosystems currently has a consensus target price of $8.00, indicating a potential upside of 233.33%. Given Rapid Micro Biosystems’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Rapid Micro Biosystems is more favorable than PositiveID.

Summary

Rapid Micro Biosystems beats PositiveID on 5 of the 9 factors compared between the two stocks.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

About PositiveID

PositiveID Corporation, a life sciences and technology company, develops and sells molecular diagnostic systems for bio-threat detection and medical testing in the United States and internationally. It operates through three segments: Molecular Diagnostics, Medical Devices, and Mobile Labs. The company develops microfluidic systems for the automated preparation and performance of biological assays to detect biological threats and analyze biological samples at the point of need. It has a portfolio of intellectual property related to sample preparation and rapid medical testing applications. The company's microfluidic bio-agent autonomous networked detector (M-BAND) technology is a bio-aerosol monitor with integrated systems for sample collection, processing, and detection modules. Its M-BAND technology analyzes air samples for the detection of pathogenic bacteria, viruses, and toxins for up to 30 days. The company's FireflyDX is an automated pathogen detection system for rapid diagnostics for clinical and point-of-need applications. Its FireflyDX system detects and identifies common pathogens and diseases, such as E. coli, methicillin-resistant staphylococcus aureus, methicillin-susceptible staphylococcus aureus, clostridium difficile, Zika virus, Ebola virus, influenza, and others. In addition, PositiveID Corporation markets Caregiver, a non-contact clinical thermometer that measures forehead temperature in adults, children, and infants for hospitals, physicians' offices, medical clinics, nursing homes and other long-term care institutions, and acute care hospitals; and manufactures and sells specialty technology vehicles for mobile laboratory, command and communications applications, and mobile cellular systems. The company was formerly known as VeriChip Corporation and changed its name to PositiveID Corporation in November 2009. PositiveID Corporation was founded in 2001 and is headquartered in Delray Beach, Florida.